Pyrazole derivatives with an ergoline skeleton, their acid addition
salts, and a process for the preparation thereof
    1.
    发明授权
    Pyrazole derivatives with an ergoline skeleton, their acid addition salts, and a process for the preparation thereof 失效
    具有麦角无骨骨架的吡唑衍生物及其酸加成盐及其制备方法

    公开(公告)号:US4632928A

    公开(公告)日:1986-12-30

    申请号:US615387

    申请日:1984-05-30

    CPC分类号: C07D457/02

    摘要: The invention relates to novel pyrazole derivatives with an ergoline skeleton of the general formula I, ##STR1## wherein x . . . y stands for a ##STR2## R is a hydrogen atom or methyl group, R.sub.1 stands for a hydrogen atom, C.sub.1-4 alkyl, carbethoxy or pyridyl-group,R.sub.2 stands for a hydrogen atom, C.sub.1-4 alkyl, allyl, C.sub.2-4 oxoalkyl-, C.sub.2-4 hydroxyalkyl or C.sub.2-4 hydroxyiminoalkyl group,R.sub.3 stands for a hydrogen atom, C.sub.1-4 alkyl, hydroxy or pyridyl group, furthermoreR.sub.2 and R.sub.3 may stand together for a group of general formula (II), ##STR3## wherein Z stands for a methylene, carbonyl, hydroxymethylene or hydroxyiminomethylene group,R.sub.4 stands for a hydrogen atom or one or two C.sub.1-4 alkyl group(s), andn is 1 or 2,and pharmaceutically acceptable salts thereof.Furthermore the invention relates to a process for the preparation of these compounds.The novel compounds are potent PGF.sub.2.alpha. receptor antagonists.

    摘要翻译: 本发明涉及具有通式I的麦角灵骨架的新型吡唑衍生物,其中x。 。 。 y表示氢原子或甲基,R1表示氢原子,C1-4烷基,乙氧基或吡啶基,R2表示氢原子,C1-4烷基,烯丙基,C2- 4个氧代烷基 - ,C2-4羟基烷基或C2-4羟基亚氨基烷基,R3代表氢原子,C1-4烷基,羟基或吡啶基,此外R2和R3可以连在一起为通式(II) 图像II其中Z表示亚甲基,羰基,羟基亚甲基或羟基亚氨基亚甲基,R4表示氢原子或一个或两个C1-4烷基,n为1或2,及其药学上可接受的盐。 此外,本发明涉及一种制备这些化合物的方法。 新型化合物是有效的PGF2α受体拮抗剂。

    3-(1-Pyrazolyl)-pyridazine derivatives and hypotensive compositions
thereof
    5.
    发明授权
    3-(1-Pyrazolyl)-pyridazine derivatives and hypotensive compositions thereof 失效
    3-(1-吡唑基) - 哒嗪衍生物及其低血压组合物

    公开(公告)号:US4224325A

    公开(公告)日:1980-09-23

    申请号:US923623

    申请日:1978-07-11

    摘要: The invention relates to compounds of general formula ##STR1## wherein R.sup.1 stands for a hydrogen atom or a C.sub.1-6 alkyl-, a C.sub.2-4 hydroxyalkyl, a C.sub.3-6 cycloalkyl or a phenyl group,R.sup.2 stands for a hydrogen, fluorine, chlorine or bromine atom or a C.sub.1-6 alkyl, a C.sub.2-4 hydroxyalkyl, a nitro or an --NR.sup.5 R.sup.6 group, wherein R.sup.5 and R.sup.6 may have the same or different meaning and stand each for a hydrogen atom or a C.sub.1-4 alkyl or a C.sub.2-4 hydroxyalkyl group,R.sup.3 stands for a hydrogen atom or a C.sub.1-6 alkyl, a C.sub.2-4 hydroxyalkyl, a C.sub.3-6 cycloalkyl or a phenyl group, a chlorine atom or a hydroxyl, amino or methoxy group,R.sup.4 stands for a carbamoyl, a cyano or an --NR.sup.7 --NHR.sup.8 group, wherein R.sup.7 and R.sup.8 may have the same or different meaning and stand each for a hydrogen atom or a C.sub.1-4 alkyl, a C.sub.2-4 hydroxyalkyl, a C.sub.1-4 alkoxycarbonyl or an --NR.sup.9 R.sup.10 group, wherein R.sup.9 and R.sup.10 may have the same or different meaning and stand each for a hydrogen atom or a C.sub.1-5 alkyl, a C.sub.2-4 hydroxyalkyl, a C.sub.3-6 cycloalkyl, a phenyl or a benzyl group, or --NR.sup.9 R.sup.10 may represent a morpholine, piperidine or piperazine ring,and their pharmaceutically acceptable acid-addition salts. Furthermore, the invention relates to a process for preparing these compounds.The novel compounds of general formula I have valuable pharmacological properties. Thus they show a considerable hypotensive effect and are capable to inhibit enzymes regulating the catabolism of prostaglandins.

    摘要翻译: 本发明涉及通式为“IMAGE”的化合物,其中R1代表氢原子或C1-6烷基,C2-4羟基烷基,C3-6环烷基或苯基,R2代表氢,氟, 氯或溴原子或C 1-6烷基,C 2-4羟基烷基,硝基或-NR 5 R 6基团,其中R 5和R 6可以具有相同或不同的含义,并且各自代表氢原子或C 1-4烷基或 C2-4羟基烷基,R3代表氢原子或C1-6烷基,C2-4羟烷基,C3-6环烷基或苯基,氯原子或羟基,氨基或甲氧基,R4代表 对于氨基甲酰基,氰基或-NR 7 -NHR 8基团,其中R 7和R 8可以具有相同或不同的含义,各自代表氢原子或C 1-4烷基,C 2-4羟烷基,C 1-4烷氧基羰基 或-NR 9 R 10基团,其中R 9和R 10可以具有相同或不同的含义,并且各自表示氢原子或C 1-5烷基,C 2-4的羟基烷基,C 3-6环烷基,苯基或苯基 或-NR9R10可以表示吗啉,哌啶或哌嗪环及其药学上可接受的酸加成盐。 此外,本发明涉及一种制备这些化合物的方法。 通式Ⅰ的新化合物具有有价值的药理学性质。 因此,它们显示出相当的降血压作用,并且能够抑制调节前列腺素分解代谢的酶。

    16-Amino-18,19,20-trinor-prostaglandin derivatives, and acid addition
salts
    6.
    发明授权
    16-Amino-18,19,20-trinor-prostaglandin derivatives, and acid addition salts 失效
    16-氨基-18,19,20-三肽前列腺素衍生物和酸加成盐

    公开(公告)号:US4418205A

    公开(公告)日:1983-11-29

    申请号:US329039

    申请日:1981-12-09

    CPC分类号: C07C405/0041 Y02P20/55

    摘要: The invention relates to new 16-amino-18,19,20-trinor-prostaglandin derivatives of general formula I, having at C-17 a substituted or unsubstituted phenyl group, wherein C-15 and C-16 may have either S or R configuration, Y stands for a hydrogen atom or a lower alkyl group, W stands for a hydrogen atom, halogen atom, hydroxy group, lower alkyl or alkoxy group, and their acid addition salts. These compounds can be prepared by removing the ester group and the p-nitrobenzyloxycarbonyl protective group of a 9.alpha.,11.alpha.,15-trihydroxy-16-p-nitrobenzyloxycarbonylamido-17-phenyl-5-cis,13-trans-18,19,20-trinor-prostadienoic acid derivative of general formula XII--wherein C-15 and C-16 may have either S or R configuration, W is as defined above, and Y stands for a lower alkyl group--in an optional sequence with the limitation that in those compounds of general formula I where W is as defined above and Y stands for a lower alkyl group, solely the p-nitrobenzyloxycarbonyl group is removed, and the resulting product of general formula I is optionally converted with an organic or inorganic acid into a salt.The new prostaglandin derivatives of the invention have valuable therapeutical properties, and can be applied in cattle raising for estrus and birth synchronization, furthermore in the veterinary praxis for the treatment of sterility, chronic endometritis and pyometry.

    摘要翻译: 本发明涉及具有C-17取代或未取代的苯基的通式I的新的16-氨基-18,19,20-三核 - 前列腺素衍生物,其中C-15和C-16可具有S或R 构型中,Y表示氢原子或低级烷基,W表示氢原子,卤素原子,羟基,低级烷基或烷氧基,以及它们的酸加成盐。 这些化合物可以通过除去9α,11α,15-三羟基-16-对硝基苄氧羰基酰胺基-17-苯基-5-顺式,13-trn-18的酯基和对硝基苄氧羰基保护基来制备, 其中C-15和C-16可以具有S或R构型,W如上所定义,Y代表低级烷基 - 在任选的序列中,具有通式XII-的19,20-三过 - 前列腺素酸衍生物 - 在通式I的那些化合物中的限制,其中W如上所定义,Y代表低级烷基,仅除去对硝基苄氧基羰基,所得到的通式I的产物任选地用有机或无机 酸变成盐。 本发明的新型前列腺素衍生物具有有价值的治疗特性,可用于发情期和出生同步的养牛,此外还适用于无菌治疗,慢性子宫内膜炎和高血压的兽医学应用。

    3-(1-Pyrazolyl)-pyridazine derivatives
    7.
    发明授权
    3-(1-Pyrazolyl)-pyridazine derivatives 失效
    3-(1-吡唑基) - 哒嗪衍生物

    公开(公告)号:US4251658A

    公开(公告)日:1981-02-17

    申请号:US914084

    申请日:1978-06-09

    CPC分类号: C07D403/04

    摘要: 3-(1-Pyrazolyl)-pyridazine derivatives of the formula I, or pharmaceutically acceptable acid addition salts thereof, which decrease high blood pressure and inhibit catabolism or prostaglandins, ##STR1## wherein R.sup.1 is hydrogen or C.sub.1-4 alkyl,R.sup.2 is hydrogen, cyano, carboxyl, carbamoyl, carbaxoyl or C.sub.1-4 alkoxycarbonyl,R.sup.3 is hydrogen or chlorine or --NR.sup.4 NHR.sup.5 or NR.sup.6 R.sup.7, wherein R.sup.4 and R.sup.5 are each hydrogen or C.sub.1-4 alkyl, wherein R.sup.6 and R.sup.7 are each hydrogen or C.sub.1-5 alkyl, C.sub.1-5 hydroxyalkyl, C.sub.3-7 cycloalkyl, phenyl or benzyl, or benzyl or phenylethyl substituted with one or two chlorine atoms or methoxy groups, or a furylmethyl, pyridylmethyl, pyrrolidine or piperazine ring, or when R.sup.7 is hydrogen, R.sup.6 is --(CH.sub.2).sub.n --NR.sup.4 R.sup.5 wherein n is an integer from 1 to 3.

    摘要翻译: 降低高血压并抑制分解代谢或前列腺素的式I的3-(1-吡唑基) - 哒嗪衍生物或其药学上可接受的酸加成盐,其中R 1是氢或C 1-4烷基, R2是氢,氰基,羧基,氨基甲酰基,碳酰基或C1-4烷氧基羰基,R3是氢或氯或-NR4NHR5或NR6R7,其中R4和R5分别是氢或C1-4烷基,其中R6和R7各自是氢或C1 或烷基,C 1-5羟基烷基,C 3-7环烷基,苯基或苄基,或被一个或两个氯原子或甲氧基取代的苄基或苯乙基,或呋喃基甲基,吡啶基甲基,吡咯烷或哌嗪环,或者当R7为氢时, R 6为 - (CH 2)n -NR 4 R 5,其中n为1至3的整数。

    16-Amino-postaglandin derivatives, their acid addition salts, and a
process for the preparation thereof
    10.
    发明授权
    16-Amino-postaglandin derivatives, their acid addition salts, and a process for the preparation thereof 失效
    16-氨基 - Postaglandin衍生物及其酸加成盐及其制备方法

    公开(公告)号:US4372973A

    公开(公告)日:1983-02-08

    申请号:US332840

    申请日:1981-12-21

    摘要: The invention relates to new 16-amino-prostaglandin derivatives of general formula I, ##STR1## wherein C-15 and C-16 may have either S or R configuration, Z stands for a hydrogen atom or a lower alkyl group, and their acid addition salts. These compounds can be prepared by removing the ester group and the p-nitrocarbobenzyloxy protective group of a 9.alpha., 11.alpha., 15-trihydroxy-16-p-nitrobenzyloxycarbonylamido-5-cis,13-trans-prostadienoic acid derivative of general formula XII--wherein C-15 and C-16 may have either S or R configuration and Z stands for a lower alkyl group--in an optional sequence with the limitation that in those compounds of general formula I where Z stands for a lower alkyl group solely the p-nitrocarbobenzyloxy group is removed, and the resulting product of general formula I is optionally converted with an organic or inorganic acid into a salt.The new prostaglandin derivatives of the invention have valuable therapeutical properties, and can be applied as abortive or oxytocic agents.

    摘要翻译: 本发明涉及通式I的新的16-氨基前列腺素衍生物,其中C-15和C-16可以具有S或R构型,Z代表氢原子或低级烷基,它们的酸 加成盐。 这些化合物可以通过除去通式9的9α,11α,15-三羟基-16-对硝基苄氧基羰基酰胺基-5-顺式,13-反式 - 前列腺烯酸衍生物的酯基和对硝基苄氧基保护基来制备 XII-其中C-15和C-16可以具有S或R构型,Z表示低级烷基 - 在任选的序列中,限制在通式I的那些化合物中,其中Z仅代表低级烷基 除去对硝基羰基苄氧基,将所得的通式I的产物任选地用有机或无机酸转化成盐。 本发明的新型前列腺素衍生物具有有价值的治疗性质,可用作流产或催产素。